Molina Healthcare shares slip 4% as medical costs pressure earnings

Molina Healthcare (MOH) shares dropped 4.3% after reporting Q2 2025 adjusted earnings of $5.48 per share, missing analyst estimates, despite revenue exceeding expectations at $11.43 billion. The underperformance was primarily due to a significant rise in medical costs, evidenced by a deteriorated medical care ratio of 90.4%, prompting the company to cut its full-year 2025 adjusted earnings guidance to no less than $19.00 per share from a consensus of $22.53.

Analysis

Molina Healthcare (MOH) reported a challenging second quarter for 2025, resulting in a 4.3% share price decline. While the company posted strong top-line growth, with revenue rising 15% year-over-year to $11.43 billion and surpassing the $10.94 billion consensus estimate, its profitability was severely impacted by rising medical costs. This was reflected in the adjusted earnings of $5.48 per share, which missed analyst expectations of $5.82. The core issue is a significant deterioration in the Medical Care Ratio (MCR), which increased to 90.4% from 88.6% in the prior-year quarter. This pressure was acute in the Medicare segment, where the MCR jumped to 90.0% from 84.9%, and the Marketplace segment, with its MCR climbing to 85.4% from 71.6%. Consequently, management has drastically cut its full-year 2025 adjusted earnings guidance to a minimum of $19.00 per share, far below the prior consensus of $22.53. Despite CEO Joseph Zubretsky framing the issue as a "temporary dislocation" and maintaining the full-year premium revenue forecast of approximately $42 billion, the magnitude of the guidance revision suggests that these cost pressures are substantial and will weigh heavily on near-term performance.

Key Decisions for Investors

• Investors should recognize the significant near-term risk signaled by the sharp reduction in full-year EPS guidance and the deteriorating Medical Care Ratio, which has directly impacted profitability despite strong revenue growth.
• The primary metric to monitor is the MCR; evidence of stabilization or improvement in subsequent quarters would validate management's 'temporary dislocation' thesis, whereas continued elevation would confirm a more persistent margin problem.
• Despite the earnings miss, the maintained revenue forecast of $42 billion and a 167,000 YoY increase in membership suggest the underlying business growth remains intact, which could present a long-term opportunity if cost trends are brought under control.
• Given the uncertainty and the market's negative reaction, it may be prudent for investors to re-evaluate their positions, as the stock is now being repriced based on a lower profitability outlook.